Genfit SA

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

07 Dec 2023 04:15:01 By Nasdaq GlobeNewswire

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

06 Dec 2023 10:30:00 By Nasdaq GlobeNewswire

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

16 Nov 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

13 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

GENFIT Reports Third Quarter 2023 Financial Information

09 Nov 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

02 Nov 2023 16:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology  

26 Sep 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update

20 Sep 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT to Participate in Upcoming Investor Conferences

05 Sep 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications

10 Aug 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

12 Jul 2023 15:10:00 By Nasdaq GlobeNewswire

Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE® trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease

30 Jun 2023 00:00:00 By Nasdaq GlobeNewswire

GENFIT Announces New Data at the European Association for the Study of the Liver (EASL) Congress 2023

07 Jun 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset

31 May 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT: May 24, 2023 Combined Shareholders Meeting results

24 May 2023 12:00:00 By Nasdaq GlobeNewswire

GENFIT Announces Publication of the Development and Validation of NIS2+™ in the Journal of Hepatology

23 May 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Reports First Quarter 2023 Financial Information

11 May 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Presents Phase 1 Clinical Data Evaluating NTZ at Digestive Disease Week® as part of its ACLF Program

09 May 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Announces Publication of Extra-Financial Performance Report 2022

27 Apr 2023 15:10:00 By Nasdaq GlobeNewswire

GENFIT Annual Combined General Meeting of May 24, 2023 — Availability of Preparatory Documents

19 Apr 2023 15:10:00 By Nasdaq GlobeNewswire